ストックスクリーナーアプリを入手
55.09
0.09%
-0.05
プレマーケット:
57.93
2.84
+5.16%
前日終値:
$55.14
開ける：
$55.85
24時間の取引高:
2.14M
Relative Volume:
0.81
時価総額：
$4.76B
収益：
$170.10M
当期純損益:
$-239.59M
株価収益率:
-19.68
EPS:
-2.8
ネットキャッシュフロー:
$-191.20M
1週間 パフォーマンス:
-6.63%
1か月 パフォーマンス:
+27.55%
6か月 パフォーマンス:
+35.92%
1年 パフォーマンス:
-8.91%
1日の値動き範囲:
$54.80
$56.20
1週間の範囲:
$52.33
$59.48
52週間の値動き範囲:
$30.04
$62.00
Crispr Therapeutics Ag Stock (CRSP) Company Profile
CRSP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
55.09 | 5.10B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-02-12 | アップグレード | TD Cowen | Sell → Hold |
| 2025-02-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
Director Makes Multi-Million Dollar Investment in Crispr Therapeutics AG! - TipRanks
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last? - MSN
Leavell Investment Management Inc. Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
William Blair Issues Positive Outlook for CRSP Earnings - MarketBeat
Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views? - MSN
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5.7%Here's What Happened - MarketBeat
B & T Capital Management DBA Alpha Capital Management Buys New Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
(CRSP) Trading Report - news.stocktradersdaily.com
Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade) - Seeking Alpha
Crispr Therapeutics AG Stock Soars Amid Strategic Moves - TipRanks
CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally - MSN
CRISPR Therapeutics Target of Unusually Large Options Trading (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Genome Engineering Market Booming as CRISPR and Gene Editing - openPR.com
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 7%Should You Buy? - MarketBeat
CRISPR Stock Surges in Recent Weeks: What's Going On?CRISPR Therapeutics (NASDAQ:CRSP) - Benzinga
10 Stocks Going Wild - Insider Monkey
CRISPR’s Medical Breakthrough: Stock Surge or Mirage? - StocksToTrade
CRISPR Therapeutics (NasdaqGM:CRSP) Advances Cardiovascular Programs With Promising Trial Results - Yahoo Finance
CRISPR Therapeutics Rises Amid Positive Cardiovascular Trials - timothysykes.com
CRISPR Therapeutics’ Bold Leap: A Revolution in Cardiovascular Treatment? - StocksToTrade
CRISPR Therapeutics Reports Landmark Advances in Cardiovascular Trials - timothysykes.com
Crispr Therapeutics AG: Strategic Positioning and Growth Potential in Gene Editing - TipRanks
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Boosted by Cambridge Investment Research Advisors Inc. - MarketBeat
CRISPR Therapeutics’ SWOT analysis: gene-editing pioneer’s stock faces pivotal year - Investing.com
Crispr Therapeutics AG Stock Soars Amid Clinical Advances - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 7.1%Here's Why - MarketBeat
Wealth Enhancement Advisory Services LLC Boosts Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2000 Dynamic Index - MarketScreener
Crispr Therapeutics’ Stock Surges on Promising Study Update - TipRanks
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
Brookline Capital Markets Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Goldman Sachs Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Crispr Therapeutics downgraded to Hold from Buy at Clear Street - TipRanks
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing - MSN
CRISPR Therapeutics Reports Positive Additional Phase 1 - GlobeNewswire
CRISPR Therapeutics (CRSP) Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 - StreetInsider
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline - GlobeNewswire
CRISPR Breakthrough: New Drug Slashes Heart Disease Risk with 86% Cholesterol Reduction in Clinical Trial - Stock Titan
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Yahoo Finance
CRISPR Therapeutics AG (CRSP): A Bull Case Theory - Yahoo Finance
Crispr Therapeutics: Face The Harsh Reality Instead Of Waiting (Rating Downgrade) - Seeking Alpha
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpWhat's Next? - MarketBeat
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Traders Buy High Volume of Call Options on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
CRISPR Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):